Likewise, the rapid evolution of HER2-directed therapies—including bispecific antibodies and antibodies–drug conjugates—and the tumor-agnostic approval of NTRK and RET inhibitors, mark an additional step toward a genomically driven therapeutic paradigm. This evidence concerns the gene ERBB2 and neoplasm.